Wegovy Hair Loss Treatment: What Patients Ask and What the Evidence Says

What the STEP 1 trial and clinical guidance record about hair shedding

The STEP 1 trial (published in the New England Journal of Medicine and the basis for semaglutide's UK weight-management licence) enrolled 1,961 adults and tracked side effects over 68 weeks. Alopecia (the clinical term used in trial reporting) appeared in roughly 3% of participants on semaglutide 2.4mg. That figure sounds small because it is: most people on Wegovy do not experience noticeable hair thinning. But for those who do, it tends to emerge around weeks 12–20, which is precisely when rapid weight loss is accelerating.

The NHS medicines page for semaglutide lists hair loss among the less common side effects, and our guide to Wegovy side effects and hair loss explains what the clinical evidence says about why this happens and how commonly it affects people in practice. What it does not list it as is permanent or follicle-damaging, because the evidence does not support that characterisation. The mechanism most clinicians and researchers point to is telogen effluvium, a well-documented response to metabolic stress rather than to Wegovy's pharmacology directly. The medicine itself is not attacking your hair; your body is responding to significant change.

If you want a fuller picture of the broader side-effect profile before starting, our Wegovy side effects guide covers the complete list drawn from the same clinical data.

Why rapid weight loss triggers telogen effluvium — and when it resolves

Hair grows in cycles. Under physiological stress, an unusually high proportion of follicles synchronise into the telogen (resting) phase and shed simultaneously around two to four months later. Significant caloric restriction, even when medically supervised and clinically appropriate, is one of the most consistent triggers in the literature. This is why hair shedding also appears with bariatric surgery, very-low-calorie diets, and other effective weight-loss interventions, it is a marker of how well treatment is working, not evidence that something has gone wrong.

Most cases of telogen effluvium resolve within six to twelve months without any specific treatment, provided the underlying trigger stabilises. On Wegovy, that usually means the shedding improves as weight loss reaches a steadier rate at or around the maintenance dose. A question our prescribers hear most weeks is whether stopping Wegovy will reverse the hair loss faster; the honest answer is that recovery is primarily driven by follicle biology, not by pausing the medicine, and stopping treatment early carries its own implications for the weight management the medicine was prescribed for.

Protein intake is particularly relevant here. Appetite suppression on semaglutide can be pronounced, and it is easy to meet a calorie deficit while inadvertently falling short on protein. Adequate dietary protein supports the hair-growth cycle; if intake drops, shedding may be prolonged. A prescriber or dietitian can advise on practical targets during treatment.

Practical steps that the evidence supports while continuing treatment

There is no licensed pharmacological treatment for Wegovy-related telogen effluvium; management is primarily supportive. That said, the evidence for several practical measures is reasonable. Prioritising protein at each meal, staying well hydrated, and taking a broad-spectrum multivitamin (if dietary variety is limited because of appetite changes) are all consistent with published dietary guidance for people on GLP-1 medicines.

Gentle hair-care habits reduce mechanical stress on fragile shafts during the shedding phase: wide-tooth combs, avoiding prolonged heat styling, and not pulling the hair tightly. None of these reverse telogen effluvium on their own, but they limit compounding breakage while regrowth catches up.

It is also worth noting that thyroid dysfunction, iron deficiency anaemia and other conditions can independently cause hair loss and may coincide with a period on Wegovy. A GP can run simple blood tests to rule these out, particularly if the pattern of loss is patchy rather than diffuse, if shedding is heavy, or if it continues well beyond the six-month mark. Our guide to Wegovy and hair loss explores the broader context, including how to distinguish telogen effluvium from other causes.

When hair loss during Wegovy treatment needs medical attention

The majority of cases are self-limiting and resolve without intervention. Seek prompt medical advice if you notice any of the following: patchy bald areas rather than diffuse thinning across the scalp; eyebrow or eyelash loss; shedding that is worsening rather than plateauing after three to four months on a stable dose; or hair loss accompanied by other symptoms such as fatigue, feeling cold, or significant mood changes. These patterns point toward causes that need investigation separately from treatment.

If you are concerned about side effects at any point during treatment, the right first step is your prescriber, and our page on hair loss from Wegovy is a helpful resource to read beforehand so you can go into that conversation well informed. You can also report any suspected medicine side effect directly through the MHRA Yellow Card scheme, which is open to patients as well as clinicians. The scheme helps regulators monitor the real-world safety profile of all medicines, including Wegovy.

For a broader look at gastrointestinal side effects that sometimes accompany treatment, the pages on managing nausea on Wegovy and semaglutide-related constipation are worth reading alongside this one. Our prescribers discuss suitability and side effects, including this one, as part of every consultation, starting a free consultation is the right next step if you are weighing up whether treatment is right for you.